CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for tella Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

tella Inc
17F, Ark Mori Bldg., 1-12-32, Akasaka
Phone: +81 359372111p:+81 359372111 SHINJUKU-KU, TKY  163-1320  Japan Fax: +81 359372112f:+81 359372112
This company is no longer actively traded on any major stock exchange.
Business Summary
tella, Inc. is a Japan-based company mainly engaged in the provision of techniques and operational knowhow associated with cell medicines, as well as the research and development of regenerative medicine and cell medicine. The Company operates through three business segments. The Cell Medicine segment is engaged in the provision of cancer treatment technology and operational method centered on dendritic cell vaccine therapy. This segment is also engaged in the provision of Services for contract medical institutions, such as cell culture system maintenance support services, management system maintenance support services and disease support services. The Medical Support segment is mainly engaged in the provision of drug development services (CROs) and genetic testing services. The Pharmaceutical segment is engaged in the development of the dendritic cell vaccine for regulatory approval as a product for cancer regenerative medicine.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/202212/31/2021Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
President, Director TomoyukiTaira 59 3/28/2019 3/27/2019
Executive Officer NaokoIino 61 3/26/2014 5/1/2010
Executive Officer HidekiMatsubara 50 3/26/2014 3/1/2011
5 additional Officers and Directors records available in full report.

Business Names
Business Name
2191
tella, Inc.

General Information
Number of Employees: 30 (As of 12/31/2021)
Outstanding Shares: 25,327,013 (As of 3/31/2022)
Shareholders: 24,137
Stock Exchange: TYO
Fax Number: +81 359372112


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, April 3, 2024